Join
Live feed
·
PRReleasevia Quantisnow
Xenon Pharmaceuticals Inc. logo

Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026

ByQuantisnow·Wall Street's wire, on your screen.
XENE· Xenon Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track XENE (Xenon Pharmaceuticals Inc.) and more on Quantisnow.